17Feb
16Feb
Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
On Friday, Corbus Pharmaceuticals Holdings, Inc. announced that data from its US and UK first-in-human dose escalation clinical study of CRB-701 (SYS6002) were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The Phase 1 Western dose escalation study enrolled participants with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression. These included several tumor types not previously explored in China. Read more >>
13Feb
Candidly Reports Near $2 Billion in Student Debt Impact, Unveils 2024 Annual Impact Report
Candidly, the market's only AI-driven student debt and savings optimization platform, today announced milestone achievements in its 2024 Annual Impact Report, including $1.8 billion in projected student debt impact and over 200,000 years saved off of student debt repayment. Read more >>
13Feb
Aras to Celebrate 25 Years of Innovation at ACE 2025 in Boston
...2025 marks a major milestone as Aras celebrates 25 years of continuous innovation while looking ahead to AI-driven PLM, advanced digital thread strategies, and scalable transformation initiatives. ACE 2025 will explore how today’s industry pioneers are establishing seamless digital threads across the entire lifecycle to enhance resilience, efficiency, and long-term competitiveness. Read more >>
12Feb
DetraPel, Inc. Selects Charlotte for Headquarters, Manufacturing
DetraPel, Inc., a clean-tech advanced materials company, has chosen to relocate its headquarters and advanced manufacturing operations to Charlotte. The company will invest $3.5 million and bring more than 30 new jobs to Southwest Charlotte. Read more >>
12Feb
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
Corbus Pharmaceuticals Holdings, Inc., today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. Read more >>
31Jan
RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office
The United States Patent and Trademark Office recently issued patent 12,178,937 entitled “Compositions and Methods for Adhesion to Surfaces,” which constitutes the 10th U.S. patent that covers the TETRANITE bone adhesive technology. This patent expands the protected technology to include injectable mineral-organic structural bone adhesive compositions that comprise alpha tricalcium phosphate. The issuance of this patent complements RevBio’s existing U.S. patent 11,638,777, which covers the method of repairing fractured bone using the aforementioned adhesive composition. These recently issued patents enlarge...
22Jan
Candidly Delivers on WEF’s 2025 Priority of “Investing in People” Through AI-Driven Student Debt and Savings Solutions
As global leaders gather for the 2025 World Economic Forum Annual Meeting to address critical challenges including workforce resilience, Candidly, the category leader in AI-driven debt and savings solutions exemplifies how innovative technologies can transform financial health. Candidly addresses the full lifecycle of education expenses and empowers workers to make simultaneous progress on paying down debt and building wealth. Through partnerships with leading employers and industry giants serving the workplace, Candidly's platform represents a model for how organizations can effectively...
22Jan
Candidly delivers next-gen benefit solutions for student debt and beyond
Candidly, the category leader in financial wellness benefits, partners with leading employers, recordkeepers, and financial services providers to deliver solutions that bring financial wellness, security, and wealth within reach — for everyone. Watch now >>
21Jan